The Effect of HLA-B27 on Susceptibility and Severity of COVID-19

Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute, Portland, Oregon, USA; Any-3, London, UK; Cedars Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, University of Texas, Houston, Texas, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody; he receives royalties from UpToDate; he receives grant support from Pfizer. HH owns Any-3, the Website that hosted the survey and donated its services. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; he receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; he receives research support from BMS and Pfizer. None of the authors believe that the above relationships influenced the contents of this report. Address correspondence to Dr. J.T. Rosenbaum, Oregon Health & Science University, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239, USA. Email: rosenbaj@ohsu.edu

Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute, Portland, Oregon, USA; Any-3, London, UK; Cedars Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, University of Texas, Houston, Texas, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody; he receives royalties from UpToDate; he receives grant support from Pfizer. HH owns Any-3, the Website that hosted the survey and donated its services. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; he receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; he receives research support from BMS and Pfizer. None of the authors believe that the above relationships influenced the contents of this report. Address correspondence to Dr. J.T. Rosenbaum, Oregon Health & Science University, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239, USA. Email: rosenbaj@ohsu.edu

Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute, Portland, Oregon, USA; Any-3, London, UK; Cedars Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, University of Texas, Houston, Texas, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody; he receives royalties from UpToDate; he receives grant support from Pfizer. HH owns Any-3, the Website that hosted the survey and donated its services. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; he receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; he receives research support from BMS and Pfizer. None of the authors believe that the above relationships influenced the contents of this report. Address correspondence to Dr. J.T. Rosenbaum, Oregon Health & Science University, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239, USA. Email: rosenbaj@ohsu.edu

Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute, Portland, Oregon, USA; Any-3, London, UK; Cedars Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, University of Texas, Houston, Texas, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody; he receives royalties from UpToDate; he receives grant support from Pfizer. HH owns Any-3, the Website that hosted the survey and donated its services. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; he receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; he receives research support from BMS and Pfizer. None of the authors believe that the above relationships influenced the contents of this report. Address correspondence to Dr. J.T. Rosenbaum, Oregon Health & Science University, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239, USA. Email: rosenbaj@ohsu.edu

Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute, Portland, Oregon, USA; Any-3, London, UK; Cedars Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, University of Texas, Houston, Texas, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody; he receives royalties from UpToDate; he receives grant support from Pfizer. HH owns Any-3, the Website that hosted the survey and donated its services. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; he receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; he receives research support from BMS and Pfizer. None of the authors believe that the above relationships influenced the contents of this report. Address correspondence to Dr. J.T. Rosenbaum, Oregon Health & Science University, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239, USA. Email: rosenbaj@ohsu.edu

Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA; Legacy Devers Eye Institute, Portland, Oregon, USA; Any-3, London, UK; Cedars Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, University of Texas, Houston, Texas, USA; OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA. This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from Abbvie for this project. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. JTR consults for Abbvie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody; he receives royalties from UpToDate; he receives grant support from Pfizer. HH owns Any-3, the Website that hosted the survey and donated its services. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; he receives research support from Lilly and Janssen. KLW consults for Pfizer, Abbvie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; he receives research support from BMS and Pfizer. None of the authors believe that the above relationships influenced the contents of this report. Address correspondence to Dr. J.T. Rosenbaum, Oregon Health & Science University, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239, USA. Email: rosenbaj@ohsu.edu